ReproSource provides diagnostic evaluation and management of recurrent pregnancy loss including robust, unique, and comprehensive testing in the areas of:
This integrated diagnostic approach helps to uncover probable causes for recurrent pregnancy loss and direct treatments that lead to establishing and maintaining a successful pregnancy.
Click the test name to learn more.
This Oligo/SNP array assay of products of conception is used to detect genomic alterations that may be associated with fetal miscarriage and should be used in conjunction with conventional cytogenetics testing and clinical evaluation of the miscarriage. A Maternal Cell Contamination test is frequently ordered along with this Oligo/SNP array assay to provide assurance that test results from fetal specimens are not influenced by contaminating maternal material. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
The ReproSource RPL Standard Panel 1.3 was designed to be in alignment with the most recent ACOG and ASRM guidelines and committee opinions for recurrent pregnancy loss testing. This panel of tests is frequently ordered along with parental karyotyping as a means of evaluating the endocrine, immune, and genetic risk factors most commonly associated with recurrent pregnancy loss.
This assay included the following tests:
Click here for more information or to order tests and panels
CertifiedBoard-certified counselors are available to help with test selection and results interpretation 1.866.GENE.INFO (1.866.436.3463).